Key result
Oral enoximone improved symptom-limited exercise capacity by 43% at 6 weeks and increased resting ejection fraction in patients with chronic congestive heart failure.
Why the study?
Does oral enoximone improve exercise tolerance, ejection fraction, and symptoms in patients with chronic congestive heart failure?
RCT (n=12)
Double-blind
Crossover
Does oral enoximone improve exercise tolerance, ejection fraction, and symptoms in patients with chronic congestive heart failure?
In a small crossover trial, oral enoximone significantly improved exercise capacity, resting ejection fraction, and symptoms in patients with moderately severe congestive heart failure.
Answers are grounded in this paper and cite their sources.
Enoximone may enhance exercise tolerance in NYHA II-III HF; extends short-term PDE-III inhibitor data from hemodynamics to functional endpoints.
The efficacy of oral enoximone, a new positive inotropic and vasodilator agent, was assessed in 12 patients with chronic congestive heart failure (New York Heart Association [NYHA] class II or III) in a double-blind randomized crossover comparison with placebo. Duration of each treatment was 6 weeks and the dose of enoximone was 150 mg tid. Efficacy was assessed by exercise tolerance, symptoms, radionuclide angiography for ejection fraction at rest and during exercise, and Holter monitoring. Two patients were withdrawn before completion of the study, one with pulmonary edema after 1 week on placebo and the other for noncompliance with enoximone therapy. Symptom-limited exercise capacity improved with enoximone by 30% and 43% (p less than .01) compared with baseline after 2 and 6 weeks treatment, respectively. Ejection fraction improved at rest (p less than .02) with enoximone but not with placebo. No change was found during exercise. Heart rate and blood pressure remained unaltered. During treatment with enoximone symptoms of exertional dyspnea and fatigue were improved and NYHA class decreased by at least one class for every patient. Holter monitoring revealed an overall increase (NS) in ectopic activity during enoximone therapy. There were no serious adverse effects and laboratory values did not change significantly. The addition of enoximone to the existing therapy of patients with moderately severe congestive heart failure provided clear and sustained subjective and objective benefit when compared with placebo.
No takes yet. Share an insight, caveat, or question.
Choraria et al. (1987) conducted an RCT in chronic congestive heart failure (n=12). enoximone vs. placebo was evaluated on Symptom-limited exercise capacity (p=<0.01). Oral enoximone improved symptom-limited exercise capacity by 43% at 6 weeks and increased resting ejection fraction in patients with chronic congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: